ALS is a complex disorder which the cause(s) are not entirely understood. However, scientists at the ALS Therapy Development Institute have discovered a number of immune system related aspects of the disease for which they are screening potential treatments, including this protein biologic.
This program has been through rigorous experiments and we continue to attempt to find appropriate dosing strategies for it.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!